Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $8.6667.

Several equities analysts have recently commented on GANX shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Monday, December 29th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th.

Gain Therapeutics Trading Up 2.6%

NASDAQ GANX opened at $1.94 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.52 and a current ratio of 2.52. Gain Therapeutics has a one year low of $1.41 and a one year high of $4.34. The company has a 50-day simple moving average of $2.36 and a 200-day simple moving average of $2.25. The firm has a market capitalization of $74.61 million, a PE ratio of -3.18 and a beta of 0.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GANX. Wealth Enhancement Advisory Services LLC bought a new position in Gain Therapeutics during the third quarter valued at about $28,000. Sprott Inc. bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $39,000. Commonwealth Equity Services LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $41,000. Millennium Management LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $45,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Gain Therapeutics in the 3rd quarter worth approximately $47,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.